Evidence map›Paper›PMID 27777967›Full record

ArticleCellular and molecular gastroenterology and hepatology2016

NOD-Like Receptor Protein 3 Inflammasome Priming and Activation in Barrett's Epithelial Cells.

Yuji Nadatani, Xiaofang Huo, Xi Zhang, Chunhua Yu, Edaire Cheng, Qiuyang Zhang, Kerry B Dunbar, Arianne Theiss, Thai H Pham, David H Wang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cellular and molecular gastroenterology and hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Yuji NadataniEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Xiaofang HuoEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
Xi ZhangEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
Chunhua YuEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
Edaire ChengEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Pediatrics, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Qiuyang ZhangEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
Kerry B DunbarEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
Arianne TheissBaylor Research Institute, Baylor University Medical Center, Dallas, Texas.
Thai H PhamEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Surgery, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas.
David H WangEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Toshio WatanabeDepartment of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Yasuhiro FujiwaraDepartment of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tetsuo ArakawaDepartment of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Stuart J SpechlerEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Rhonda F SouzaEsophageal Diseases Center, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Department of Medicine, VA North Texas Health Care System and University of Texas Southwestern Medical Center, Dallas, Texas; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.
Southwestern Medical Center · USOsaka City University · JPBaylor University Medical Center · USChildren's Medical Center · US

Funding

Role of Acid in the Development of Barrett's EsophagusR01DK063621 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI SOUZA, RHONDA F, SPECHLER, STUART JON · 2002 to 2015
$3.4M
ANTECEDANTS SEQUELAE OF CHILDHOOD ONSET DISEASEK12HD068369 · NICHD · UT SOUTHWESTERN MEDICAL CENTER · PI SKAPEK, STEPHEN X · 2011 to 2020
$3.0M
Hedgehog signaling in the development of Barrett's esophagusR01DK097340 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI WANG, DAVID H · 2013 to 2017
$1.4M
The Role of Periostin and Th2 Cytokines in Eosinophilic Esophagitis FibrogenesisK08DK099383 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI CHENG, EDAIRE · 2013 to 2016
$595k
Mechanisms of Response to Reflux-Induced Oxidative Stress in Barrett's EsophagusI01BX002666 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · PI DUNBAR, KERRY BRANDT, SOUZA, RHONDA F · 2015 to 2018
–
BLRD VA I01 BX002666NICHD NIH HHS K12 HD068369NIDDK NIH HHS K08 DK099383NIDDK NIH HHS R01 DK063621NIDDK NIH HHS R01 DK097340
6 · The paper itself

Abstract

BACKGROUND &

aimsMicrobial molecular products incite intestinal inflammation by activating Toll-like receptors (TLRs) and inflammasomes of the innate immune system. This system's contribution to esophageal inflammation is not known. Gram-negative bacteria, which dominate the esophageal microbiome in reflux esophagitis, produce lipopolysaccharide (LPS), a TLR4 ligand. TLR4 signaling produces pro-interleukin (IL)1β, pro-IL18, and NOD-like receptor protein 3 (NLRP3), which prime the NLRP3 inflammasome. Subsequent NLRP3 inflammasome activation cleaves caspase-1, inducing secretion of proinflammatory cytokines and pyroptosis (inflammatory cell death). We explored LPS effects on NLRP3 inflammasome priming and activation in esophageal cells.

methodsWe exposed esophageal squamous and Barrett's epithelial cells to LPS and measured the following: (1) TLR4, pro-IL1β, pro-IL18, and NLRP3 expression; (2) caspase-1 activity; (3) tumor necrosis factor-α, IL8, IL1β, and IL18 secretion; (4) lactate dehydrogenase (LDH) release (a pyroptosis marker); and (5) mitochondrial reactive oxygen species (ROS). As inhibitors, we used acetyl-Tyr-Val-Ala-Asp-CHO for caspase-1, small interfering RNA for NLRP3, and (2-(2,2,6,6,-Tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl)triphenylphosphonium chloride for mitochondrial ROS.

resultsSquamous and Barrett's cells expressed similar levels of TLR4, but LPS induced TLR4 signaling that increased tumor necrosis factor-α and IL8 secretion only in Barrett's cells. Barrett's cells treated with LPS showed increased expression of pro-IL18, pro-IL1β, and NLRP3, and increased mitochondrial ROS levels, caspase-1 activity, IL1β and IL18 secretion, and LDH release. Acetyl-Tyr-Val-Ala-Asp-CHO, NLRP3 small interfering RNA, and Mito-TEMPO all blocked LPS-induced IL1β and IL18 secretion and LDH release.

conclusionsIn Barrett's cells, LPS both primes and activates the NLRP3 inflammasome, causing secretion of proinflammatory cytokines and pyroptosis. By triggering molecular events promoting inflammation, the esophageal microbiome might contribute to inflammation-mediated carcinogenesis in Barrett's esophagus.

Indexed as

Ac-YVAD-CHO, acetyl-Tyr-Val-Ala-Asp-CHOAIM, absent in melanomaASC, apoptosis-associated speck-like protein containing a caspase recruitment domainATP, adenosine triphosphateCytokineDAMP, damage-associated molecular patternEsophageal Squamous CellGAPDH, glyceraldehyde-3-phosphate dehydrogenaseGERDGERD, gastroesophageal reflux diseaseIL1βIL, interleukinLDH, lactate dehydrogenaseLPS, lipopolysaccharidemRNA, messenger RNANF-κB, nuclear factor-κBNLRP3, NOD-like receptor protein 3NOD, nucleotide-binding domain, leucine-rich repeat containing proteinsPAMP, pathogen-associated molecular patternPBS, phosphate-buffered salinepro, proteinPRRs, pattern-recognition receptorsPyroptosisqPCR, quantitative reverse-transcription polymerase chain reactionROS, reactive oxygen speciesRT-PCR, reverse-transcription polymerase chain reactionsiRNA, small interfering RNATLR, Toll-like receptorTNF, tumor necrosis factor

Identifiers

PMID27777967
PMCPMC5042564
OpenAlexW2297198954

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.